Israeli global therapeutics company DarioHealth, a digital health firm that uses big data to offer diabetes management, announced last week a new partnership with DigitalHealth.London (DH.L) to help bring its digital therapeutics technology to the UK to assist patients in better managing their chronic health conditions.
The partnership is part of the UK Israel Dangoor Health Initiative, which
aims to partner Israeli digital health companies with the UK National Health Service (NHS), and was first announced last year, in collaboration with the UK Israel Tech Hub, and Dangoor Education.
Get our weekly newsletter directly in your inbox!Sign up
DigitalHealth.London aims to speed up the development and scaling of digital innovation across healthcare and spearhead adoption by the NHS.
DarioHealth offers a self-administered diabetes management platform. The company’s flagship product, the Dario Blood Glucose Monitoring System, is a pocket-sized, all-in-one smart glucose meter, which syncs with the Dario Smart Diabetes Management app to measure, record and track blood glucose levels. The app records carbs intake, insulin medication, and physical activity. The app, through its built-in GPS location function, also enables partnering pharmacies to contact patients in case of hypoglycemia emergencies.
Its unique mission, which has an emphasis on behavioral engagement with users, through the offering of personalized interventions, is the kind of approach that will really benefit patients as part of the UK initiative.
“With 25 percent of middle-aged adults suffering from hypertension and 2.6 million people diagnosed with diabetes, the NHS needs the very best in digital innovation in order to manage chronic disease conditions successfully, now and into the future,” said Dror Bacher, DarioHealth chief operating officer, in a statement.
“DarioHealth is well-positioned to offer quality digital therapeutic interventions for managing chronic conditions and looks forward to exploring opportunities for integration and partnership with both primary and secondary care providers. Through our collaboration, we will examine the best ways to develop new Dario digital therapeutics solutions for people with chronic conditions within the framework of the NHS,” he added.